AOD-9604

Modified fragment of human growth hormone (amino acids 176-191) with an added tyrosine at the N-terminus. Stimulates lipolysis and inhibits lipogenesis via beta-3 adrenergic receptor modulation without affecting IGF-1 levels, blood glucose, or tissue growth. Acts on fat cells without the growth-promoting effects of full GH.

Half-life

Variable (limited pharmacokinetic data)

Bioavailability

Subcutaneous (limited data on oral bioavailability)

Route

subcutaneous, oral

Evidence tier

T3 — Community / emerging

Optimization pillars

fat-loss

References

1 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

100–250 mcg/day

Fat loss support

moderate

250–500 mcg/day

Standard fat loss protocol

aggressive

500–1000 mcg/day

Aggressive fat loss

Monitoring

fasting-glucose
fasting-insulin
lipid-panel

Contraindications

active-cancer
pregnancy

References

PMID:11713213Effects of a growth hormone-releasing peptide fragment on body weight in obese mice — Obes Res, 2001

Notes

AOD-9604 is a fragment of growth hormone engineered to retain the fat-burning properties while eliminating the growth-promoting effects. Elegant idea. The problem is the evidence base. The rodent data is interesting. The human data is sparse. A Phase IIb clinical trial for obesity showed no statistically significant weight loss versus placebo. TGA in Australia approved it for osteoarthritis, not fat loss. The mechanism is plausible. The clinical proof is insufficient to justify a strong recommendation.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See AOD-9604 in a protocol matched to you